Journal of the American Society of Nephrology, Vol 1, Issue 2 150-161, Copyright © 1990 by American Society of Nephrology

REVIEWS

Biocompatibility of hemodialysis membranes

AK Cheung
Medical Service, Veterans Affairs Medical Center, Salt Lake City, UT 84148.

Exposure of blood to hemodialysis membranes results in numerous interactions between the blood elements and the membrane. Transformation and adsorption of plasma proteins (such as complement) and activation of blood cells (such as neutrophils and monocytes) have been studied most extensively by nephrologists in recent years. There is no consensus on the definition of biocompatibility for dialyzer membranes. An operational definition of biocompatibility is the lack of any perturbation of blood constituents. According to this "inert surface" definition, a membrane (for example, one that adsorbs beta 2- microglobulin) can be considered as bioincompatible and yet desirable. Because of the multitude of blood-membrane interactions that may occur during hemodialysis, multiple criteria for biocompatibility needs to be applied in the classification of membranes. A certain bioincompatible phenomenon can be further classified as beneficial or deleterious depending on its biological effects as well as its acute and chronic impacts on the dialysis patient.

This article has been cited by other articles:

				D. H. Krieter, A. Morgenroth, A. Barasinski, H.-D. Lemke, O. Schuster, B. von Harten, and C. Wanner Effects of a polyelectrolyte additive on the selective dialysis membrane permeability for low-molecular-weight proteins Nephrol. Dial. Transplant., February 1, 2007; 22(2): 491 - 499. [Abstract] [Full Text] [PDF]

				Y. Hasuike, T. Nakanishi, R. Moriguchi, Y. Otaki, M. Nanami, Y. Hama, M. Naka, K. Miyagawa, M. Izumi, and Y. Takamitsu Accumulation of cyanide and thiocyanate in haemodialysis patients Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1474 - 1479. [Abstract] [Full Text] [PDF]

				J. Galle and S. Seibold Has the time come to use antioxidant therapy in uraemic patients? Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1452 - 1455. [Full Text] [PDF]

				J. Galle and S. Seibold Has the time come to use antioxidant therapy in uraemic patients? Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1452 - 1455. [Full Text]

				A. Papayianni, E. Alexopoulos, P. Giamalis, L. Gionanlis, A.-M. Belechri, P. Koukoudis, and D. Memmos Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events Nephrol. Dial. Transplant., March 1, 2002; 17(3): 435 - 441. [Abstract] [Full Text] [PDF]

				T. MIYATA, K. KUROKAWA, and C. VAN YPERSELE DE STRIHOU Advanced Glycation and Lipoxidation End Products: Role of Reactive Carbonyl Compounds Generated during Carbohydrate and Lipid Metabolism J. Am. Soc. Nephrol., September 1, 2000; 11(9): 1744 - 1752. [Full Text]

				A. MARTÍN-MALO, J. CARRACEDO, R. RAMÍREZ, A. RODRIGUEZ-BENOT, S. SORIANO, M. RODRIGUEZ, and P. ALJAMA Effect of Uremia and Dialysis Modality on Mononuclear Cell Apoptosis J. Am. Soc. Nephrol., May 1, 2000; 11(5): 936 - 942. [Abstract] [Full Text]

				T. Suda, K. Hiroshige, T. Ohta, Y. Watanabe, M. Iwamoto, K. Kanegae, A. Ohtani, and Y. Nakashima The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients Nephrol. Dial. Transplant., March 1, 2000; 15(3): 396 - 401. [Abstract] [Full Text] [PDF]

				R. Thadhani, M. Pascual, and J. V. Bonventre Acute Renal Failure N. Engl. J. Med., May 30, 1996; 334(22): 1448 - 1460. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673